spacer
CDC Home > HIV/AIDS > Topics > Statistics and Surveillance > Reports
Selected Measures of Access to and Utilization of Treatment and Prophylaxis for HIV-Infected Persons
spacer
HIV/AIDS Surveillance Supplemental Report - Volume 9, Number 3
spacer
Selected Measures of Access to and Utilization of Treatment and Prophylaxis for HIV-Infected Persons
space
arrow Cover
space
arrow Commentary
space
arrow Table 1
space
arrow Table 2
space
arrow Table 3
space
arrow Table 4
space
arrow Table 5
space
arrow Table 6
space
arrow Table 7
space
arrow Table 8
space
arrow Table 9
space
arrow Table 10
space
arrow Table 11
space
arrow Table 12
space
arrow Table 13
space
arrow Table 14
space
arrow Table 15
space
arrow Technical Notes
space
 
LEGEND:
PDF Icon   Link to a PDF document
Non-CDC Web Link   Link to non-governmental site and does not necessarily represent the views of the CDC
Adobe Acrobat (TM) Reader needs to be installed on your computer in order to read documents in PDF format. Download the Reader.
spacer spacer
spacer
Skip Nav spacer
Contents
spacer
spacer
View PDF PDF icon
 
Cover
 
Commentary
 
A. Antiretroviral Medications
Table 1 HIV-infected patients ever prescribed antiretroviral therapy by data source and sex
Table 2 HIV-infected patients ever prescribed antiretroviral therapy by data source and race/ethnicity
Table 3 HIV-infected patients currently prescribed antiretroviral therapy by data source and insurance status
Table 4 HIV-infected patients currently prescribed antiretroviral therapy by data source and sex
Table 5 HIV-infected patients currently prescribed antiretroviral therapy by data source and race/ethnicity
Table 6 HIV-infected patients currently prescribed highly active antiretroviral therapy (HAART) by data source and insurance status
Table 7HIV-infected patients currently prescribed highly active antiretroviral therapy (HAART) by data source and sex
Table 8HIV-infected patients currently prescribed highly active antiretroviral therapy (HAART) by data source and race/ethnicity
 
B. Pneumocystis carinii Pneumonia
Table 9 HIV-infected patients ever diagnosed with Pneumocystis carinii pneumonia (PCP) by data source and sex
Table 10 HIV-infected patients ever diagnosed with Pneumocystis carinii pneumonia (PCP) by data source and race/ethnicity
Table 11 HIV-infected patients currently prescribed Pneumocystis carinii pneumonia (PCP) prophylaxis by data source and insurance status
Table 12 HIV-infected patients prescribed primary Pneumocystis carinii pneumonia (PCP) prophylaxis by data source and sex
Table 13 HIV-infected patients prescribed primary Pneumocystis carinii pneumonia (PCP) prophylaxis by data source and race/ethnicity
 
C. Tuberculin Skin Test
Table 14 HIV-infected patients receiving a tuberculin skin test (TST) by data source and sex
Table 15 HIV-infected patients receiving a tuberculin skin test (TST) by data source and race/ethnicity
 
Technical Notes
spacer
Last Modified: June 21, 2006
Last Reviewed: June 21, 2006
Content Source:
Divisions of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
spacer
spacer
spacer
Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
spacer
spacer
spacer Safer, Healthier People
spacer
Centers for Disease Control and Prevention, 1600 Clifton Road, N.E., Atlanta, GA 30333, U.S.A.
Phone: 1-404-639-3311 / Public Inquiries: 1-800-CDC-INFO (232-4636) / TTY: 1-888-232-6348		 spacer USA.gov: The U.S. Government's Official Web PortalDHHS Department of Health
and Human Services